论文部分内容阅读
目的通过对长江流域6城市2004—2007年肿瘤分子靶向治疗药物利用分析,评价该地区肿瘤分子靶向治疗。方法对6城市入网医院2004—2007年临床应用的肿瘤分子靶向治疗药物数据资料进行统计分析,对用药金额和用药频度进行排序。结果长江流域6城市肿瘤分子靶向药物用药增长迅速,由2004年的1924万元增加到2007年的1.73亿元,年均增长率107.98%。上海用药金额居首位,成都年均增长率最快。抗信号转导药的增长显著快于抗肿瘤单克隆抗体(单抗),DDDs排序均位于抗肿瘤单抗之前。结论长江流域6城市肿瘤分子靶向治疗药物用药增长迅速,显示肿瘤靶向治疗与传统化疗结合的良好趋势。抗信号转导药物的应用较为广泛,可能与药物的适应证及价格因素均有关系。
Objective To evaluate the molecular targeted therapy of tumor in the six cities in the Yangtze River valley from 2004 to 2007. Methods Statistical data were collected from clinical data of molecular target therapy for cancer from 2004 to 2007 in 6 hospital networked hospitals in China. The medication amount and medication frequency were ranked. Results In 6 cities in the Yangtze River basin, the use of targeted molecular drugs for cancer increased rapidly from 19.24 million yuan in 2004 to 173 million yuan in 2007, with an average annual growth rate of 107.98%. Shanghai topped the amount of medication, Chengdu, the fastest average annual growth rate. The growth of anti-signal transducers was significantly faster than that of anti-tumor monoclonal antibodies (mAbs), with DDDs ranked prior to anti-tumor mAbs. Conclusion Sixty-three cities in the Yangtze River basin have been rapidly increasing their use of molecular targeted therapy drugs, indicating a good trend of combining tumor-targeted therapy with traditional chemotherapy. Anti-signal transduction drugs are widely used, may be related to drug indications and price factors are related.